Evidence map›Paper›PMID 28289402›Full record

ArticleFrontiers in endocrinology2017

Medical Therapy with Pasireotide in Recurrent Cushing's Disease: Experience of Patients Treated for At Least 1 Year at a Single Center.

Chris G Yedinak, Sarah Hopkins, Jessica Williams, Aly Ibrahim, Justin Schultz Cetas, Maria Fleseriu

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Chris G YedinakDepartment of Medicine-Endocrinology, Diabetes, and Clinical Nutrition, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA; Department of Neurological Surgery, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA.
Sarah HopkinsDepartment of Medicine-Endocrinology, Diabetes, and Clinical Nutrition, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA; Department of Neurological Surgery, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA.
Jessica WilliamsDepartment of Medicine-Endocrinology, Diabetes, and Clinical Nutrition, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA; Department of Neurological Surgery, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA.
Aly IbrahimDepartment of Medicine-Endocrinology, Diabetes, and Clinical Nutrition, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA; Department of Neurological Surgery, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA.
Justin Schultz CetasDepartment of Medicine-Endocrinology, Diabetes, and Clinical Nutrition, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA; Department of Neurological Surgery, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA.
Maria FleseriuDepartment of Medicine-Endocrinology, Diabetes, and Clinical Nutrition, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA; Department of Neurological Surgery, OHSU Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA.
Neurological Surgery · USOregon Health & Science University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subcutaneous (SC) injection of pasireotide, a somatostatin analog, is approved for the treatment of adults with Cushing's disease (CD) for whom pituitary surgery was unsuccessful or is not an option. We highlight the symptomatic and biochemical improvement of six patients with recurrent CD treated with pasireotide SC at a single center for at least 1 year. Patients were treated either through commercial use (

Indexed as

Cushing’s diseasehyperglycemiapasireotidereal-world clinical experiencerecurrent Cushing’s disease

Identifiers

PMID28289402
PMCPMC5327352
OpenAlexW2593810616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.